6-(2-Chloro-4-trifluoromethoxyphenyl)-9-dicyclopropylmethyl-8-ethylpurine | 219733-95-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(2-Chloro-4-trifluoromethoxyphenyl)-9-dicyclopropylmethyl-8-ethylpurine
• 英文别名: 6-(2-chloro-4-trifluoromethoxyphenyl)-9-(dicyclopropylmethyl)-8-ethyl-9H-purine；6-[2-Chloro-4-(trifluoromethoxy)phenyl]-9-(dicyclopropylmethyl)-8-ethylpurine
• CAS: 219733-95-6
• 化学式: C₂₁H₂₀ClF₃N₄O
• 分子量: 436.864
• InChiKey: MSAXSRXBRXZPJL-UHFFFAOYSA-N

物化性质

• 沸点：
  525.585±50.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  1.550±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  52.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Novel imidazopyrimidinyl and imidazopyri dinyl derivatives
  申请人：——

  公开号：US20040229887A1

  公开（公告）日：2004-11-18

  Provided herein are compounds of the formula (I): 1 as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by execssive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.

  本文提供了公式（I）化合物，以及其立体异构体和药学上可接受的盐。这些化合物由于其对CRF的拮抗作用，在治疗许多由于CRF过度表达引起的疾病方面非常有用。这些疾病包括：情感障碍、焦虑、抑郁、头痛、肠易激综合征、创伤后应激障碍、上核性麻痹、免疫抑制、阿尔茨海默病、亨廷顿病、帕金森病、肌萎缩侧索硬化、胃肠疾病、厌食症或其他进食障碍、药物成瘾、药物或酒精戒断症状、炎症性疾病、心血管或心脏相关疾病、生育问题、人类免疫缺陷病毒感染、出血性应激、肥胖症、头部和脊髓创伤、癫痫、中风、溃疡、肌萎缩侧索硬化和低血糖症。
• [EN] IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] IMIDAZOPYRIMIDINES ET IMIDAZOPYRIDINES UTILES POUR TRAITER DES TROUBLES NEUROLOGIQUES
  申请人：DU PONT PHARMACEUTICALS COMPANY

  公开号：WO1999001454A1

  公开（公告）日：1999-01-14

  (EN) Corticotropin releasing factor (CRF) antagonists of formula (I) and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.(FR) L'invention concerne des antagonistes du facteur de libération de la corticotrophine (CRF) représentés par la formule (I), et leur utilisation pour traiter des troubles psychiatriques et des affections neurologiques, des troubles liés à l'anxiété, des troubles de stress post-traumatique, des troubles de paralysie supranucléaire et de l'alimentation, ainsi que des troubles immunitaires, cardiovasculaires ou cardiaques, et une hypersensibilité du côlon associée à des troubles psychopathologiques et au stress chez les mammifères.

  抗皮质激素释放因子（CRF）拮抗剂的化学式（I），以及它们在治疗哺乳动物的精神障碍和神经疾病、焦虑相关障碍、创伤后应激障碍、上核麻痹和进食障碍，以及治疗免疫、心血管或与心脏相关的疾病和与心理病理障碍和压力相关的结肠过敏性方面的应用。
• [EN] IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES<br/>[FR] DERIVES IMIDAZOPYRIMIDINYLES ET IMIDAZOPYRIDINYLES
  申请人：DU PONT PHARM CO

  公开号：WO2001044248A1

  公开（公告）日：2001-06-21

  Provided herein are compounds of formula (I): wherein D is an aryl or heteroaryl ring containing 1 - 2 C1-4 haloalkoxy groups; as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by excessive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.

  本文提供了一些化合物的公式(I)：其中D是一个含有1-2个C1-4卤代烷氧基的芳基或杂芳基环，以及其立体异构体和药学上可接受的盐。由于它们拥有拮抗CRF的能力，这些化合物在治疗许多由于CRF过度表达所导致的疾病方面具有用处。这些疾病包括但不限于：情感障碍、焦虑、抑郁、头痛、肠易激综合征、创伤后应激障碍、上行性麻痹、免疫抑制、阿尔茨海默病、亨廷顿病、帕金森病、肌萎缩性侧索硬化、胃肠疾病、厌食症或其他进食障碍、药物成瘾、药物或酒精戒断症状、炎症性疾病、心血管或与心脏有关的疾病、生育问题、人类免疫缺陷病毒感染、出血性应激、肥胖症、头部和脊髓创伤、癫痫、中风、溃疡、肌萎缩性侧索硬化和低血糖症。
• Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
  申请人：——

  公开号：US20030114468A1

  公开（公告）日：2003-06-19

  Corticotropin releasing factor (CRF) antagonists of formula (I): 1 and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

  促肾上腺皮质激素释放因子（CRF）拮抗剂的化学式（I）：1及其在治疗精神障碍和神经系统疾病、焦虑相关疾病、创伤后应激障碍、上行性麻痹和进食障碍以及治疗免疫、心血管或与心脏相关的疾病以及与心理病理紊乱和压力相关的结肠过敏性疾病在哺乳动物中的应用。
• IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：Du Pont Pharmaceuticals Company

  公开号：EP0994877A1

  公开（公告）日：2000-04-26